- 10.8.2026
- News
- Stanford Research
Veterans Experience Major PTSD and Depression Relief From Psychedelic Drug Ibogaine
This news report examines Stanford Medicine’s one-year follow-up study of Special Operations veterans who received ibogaine treatment, supported in part by VETS, and how the findings add to the growing body of research and federal attention on psychedelic-assisted therapy for veterans.
- 10.6.2026
- Stanford Research
- News
One year after taking ibogaine, veterans find continued relief from PTSD
A new Stanford Medicine study published in Translational Psychiatry follows Special Operations veterans for one year after ibogaine treatment, funded by VETS at a vetted, third-party facility, offering the most extensive look to date at the long-term potential of this therapy for PTSD, depression, and anxiety.
- 8.26.2026
- News
MDMA and the FDA, Take Two
VETS Policy Director Logan Davidson weighs in on Resilient Pharmaceuticals' renewed FDA application for MDMA-assisted therapy, calling it a meaningful step toward the rigorous, science-backed treatment options veterans with treatment-resistant PTSD deserve.
- 8.20.2026
- News
VA Benefits: Trump Shares Update on Psychedelic Drug Treatment for Veterans
President Trump announced that HHS Secretary RFK Jr. received the University of Miami's original 1994 ibogaine FDA application to accelerate psychedelic research access for veterans, with VETS co-founder and CEO Amber Capone comments that "veterans need to understand that these treatments are not for everyone and they need careful screening, medical oversight, preparation, and follow-up."
- 7.13.2026
- News
Massachusetts House Advances Psychedelic Therapy Pilot Program
Massachusetts lawmakers advanced legislation to create a five-year psychedelic-assisted therapy pilot program, with VETS playing a key advocacy role by supporting the measure and celebrating it as a major step toward expanding safe, regulated access to psychedelic-assisted therapy for veterans and others with serious mental health conditions.
